Skip to main content

Table 1 Frequency of mutations in the RAS-MAPK genes of different adult and childhood cancers (source: COSMIC database, April 6th, 2020)

From: A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma

Level

Gene

Mutations

Neuroblastoma (%)

Brain (%)

Breast (%)

Colorectal (%)

Blood (%)

Lung (%)

Skin (%)

Receptor

ALK

F1174L, R1275Q, R1245V

6.3

0.8

7.3

5.7

5.6

4.4

9.1

Protein adaptor

SHC1

E343D

0.1

0.1

0.6

2.0

0.2

0.7

1.0

GRB2

  

0.4

2.2

0.6

1.0

0.3

0.9

PTPN11

Mutations in SH2 and PTP domains

1.0

1.7

1.3

1.7

4.7

0.9

2.4

SOS

SOS1

N993Sfs*5

0.1

0.7

3.3

3.5

1.3

2.1

3.7

RAS

N-RAS

Q61K/E/L, G13R, A59T

0.7

1.0

0.5

3.7

9.5

0.8

15.0

K-RAS

G12V

 

0.8

1.4

32.4

4.9

14.8

2.8

H-RAS

Q61K

0.1

0.0

0.6

0.9

0.2

0.5

10.6

RAF

BRAF

V600E. F595L. R719P

0.1

4.7

2.1

12.3

8.2

2.2

41.0

RAF1

L397V

0.1

0.3

1.6

2.3

0.6

1.0

3.1

ARAF

  

0.2

0.6

2.0

0.3

1.4

1.9

MEK1/2

MAP2K1

K57N

 

0.3

1.8

1.9

2.2

0.7

4.7

MAP2K2

c.920-66G > T

0.1

0.1

0.8

1.3

0.5

0.6

2.1

ERK1/2

MAPK3

E367D

0.1

0.1

0.4

1.0

0.2

0.3

1.4

MAPK1

  

0.4

1.6

1.3

1.1

0.3

1.5

NF

NF1

Inactivating nonsense mutations

1.2

7.2

6.1

9.5

3.5

7.2

16.8